Blog Posts

340B Provides Benefits, Needs Reform, Says Literature Review

A JAMA Health Network literature review found that the 340B program provides a range of benefits but needs reforms.
The 340B program has provided a range of benefits but also needs reforms, according to a recent review of published [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Unlocking the Value of 340B Consultants: Their Roles and Responsibilities

SPONSORED CONTENT

In the complex landscape of healthcare, the 340B program plays a vital role in ensuring that vulnerable patients with limited financial resources have access to affordable medications. It enables qualified covered entities to maximize their resources and offer a wider range of benefits and services to those in need.

Managing this program efficiently and

Read More »

340B’s Footprint in Medicare Part D Is Growing, Study Says

A JAMA Health Forum study co- authored by Sean Dickson found the 340B program's footprint in Medicare Part D is increasing.
340B covered entities captured nearly half (49.9%) of their 340B-eligible prescriptions billed to Medicare Part D in 2020, up from [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Sen. Cassidy Mum on Next Steps for 340B Provider Probes

Sen. Bill Cassidy (R-La.) has launched multiple inquiries into 340B providers but has not yet specified how he intends to use any findings.
The influential senator who launched an inquiry into how two community health centers and two 340B hospitals use 340B savings [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Senate Democrats Seek Drug Pricing Testimony from Three Pharma CEOs

Sen. Bernie Sanders (I-Vt.) and 10 Democrats on an influential committee invited the CEOs of three pharma companies to testify at a January hearing.
Senate Democrats on an influential committee invited the CEOs of three major pharmaceutical companies to testify at a January hearing [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Two Drugmakers Offer Refunds for 340B Overcharges

Two drugmakers, Mallinckrodt's subsidiary SpecGx and Novo Nordisk, owe refunds to 340B providers for certain overcharges.
Two drugmakers will offer refunds to 340B providers for overcharges in recent years. Drug manufacturer Mallinckrodt’s SpecGx generic pharmaceutical subsidiary [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Michigan Bill Introduced to Protect 340B Contract Pharmacy Arrangements

Michigan state Rep. Alabas Farhat (D) introduced a bipartisan bill designed to protect 340B contract pharmacy arrangements in the state.
Michigan state lawmakers this week introduced a bill designed to protect 340B contract pharmacy arrangements from drug manufacturer restrictions. On [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B Reforms Urged by Centrist Democrat Group with Drugmaker Ties

Darbin Wofford, a health policy advisor at Third Way, said his organization is urging Congressional Democrats to adopt 340B program reforms.
A center-left group that has received pharmaceutical industry funding is urging a series of 340B reforms that it hopes to [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Apexus Asks Appeals Court to Affirm Dismissal of Contract Breach Lawsuit

Apexus asked the 9th U.S. Circuit Court of Appeals to dismiss a lawsuit claiming it failed to negotiate sub-340B ceiling price discounts on HIV/AIDS drugs.
Apexus, the 340B prime vendor, asked a federal appeals court to affirm a lower court’s dismissal of claims that it [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Jazz Pharmaceuticals Posts Refund Notice on HRSA Website

Jazz Pharmaceuticals owes refunds to 340B providers, according to a notice posted on HRSA's website.
Jazz Pharmaceuticals owes refunds to 340B providers, according to a notice posted on the Health Resources and Services Administration’s Office [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report